Key result
BioBeat cuffless patch enables continuous 24-hour monitoring over traditional cuff-based ABPM.
Cuffless, sensor-based ambulatory blood pressure monitoring using photoplethysmography offers a continuous alternative to traditional cuff-based systems for hypertension management.
Hypertension affects nearly 47% of US adults, yet traditional cuff-based monitoring often fails to provide the longitudinal data required for effective treatment due to patient noncompliance and the prevalence of white coat syndrome. BioBeat addresses this clinical gap with its FDA-cleared, cuffless ambulatory blood pressure monitoring (ABPM) system, which utilizes a proprietary photoplethysmography (PPG) disposable patch to continuously capture 13 vital signs over 24 hours. By integrating real-time physiological data with patient-logged behavioral events through a cloud-based platform, the technology enables more precise medication titration and provides a high-fidelity alternative to intermittent, oscillometric testing. Currently adopted by over 160 hospitals and utilized in numerous pharmaceutical clinical trials, this transition to continuous, sensor-based monitoring represents a paradigm shift in cardiovascular care, facilitating a move toward personalized, data-driven management of chronic hypertension.
No takes yet. Share an insight, caveat, or question.
Chad Andresen (2026) studied Hypertension. BioBeat cuffless ambulatory blood pressure monitoring (ABPM) system vs. traditional cuff-based monitoring was evaluated. The BioBeat cuffless ambulatory blood pressure monitoring system provides continuous 24-hour vital sign capture via a photoplethysmography patch as an alternative to traditional cuff-based testing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: